A significant association was found between p16INK4A promoter methylation and RCC (OR = 2.77, 95% CI = 1.36 - 5.66, P = 0.005), including in 582 of the cancer patients and 422 of the controls (Figure 2). Here, CDKN2A is linked to renal cell carcinoma.